Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2006, 31(9): 788
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2006 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2006.031.09.1030940
Wang, Y., Bolos, J., Serradell, N.
Prostaglandin analogues have been extensively studied and used for lowering/controlling the elevated intraocular pressure (IOP) that causes glaucoma. In the search for a drug candidate with stronger and more consistent IOP-lowering activity while producing milder side effects than currently available drugs, tafluprost was synthesized and selected for further evaluation. Preclinical studies carried out in mice, cats and monkeys showed that tafluprost at a concentration of 0.005% has a potent IOP-lowering effect. Pharmacokinetic studies demonstrated rapid absorption into ocular tissues and entry into the systemic circulation. Results from phase I and II clinical trials indicated that tafluprost had a stronger IOP-lowering effect than latanoprost, with fewer and milder local side effects. The compound has been submitted for regulatory approval in Japan by Santen.

Full Text: HTMLPDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences